Startseite Kongressberichte 2021 63rd ASH Annual Meeting and Exposition In-Person/Virtual MDS Treatment of HIgh Risk and Relapsed/Refractory Myelodysplastic Syndrome

637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment of HIgh Risk and Relapsed/Refractory Myelodysplastic Syndrome


Alexandre Bazinet, Elias J. Jabbour, Hagop Kantarjian, et al.

Treatment with AZA-VEN was tolerable and effective in this high-risk patient group, with a very high ORR. AZA-VEN was shown to be an effective bridge to aHSCT.



Rami S. Komrokji, Najla Al Ali, Onyee Chan, et al.

In the higher risk MDS, first-line hypomethylating agents / Venetoclax achieved significantly higher complete response rates including the mutated ASXL-1 MDS compared to first-line hypomethylating agents (HMA) alone. The data suggest promising activity in those who received first-line HMA / Venetoclax and AHSCT (2-year OS 91%). The Venetoclax-add-back strategy to HMA after first-line HMA failure has clinical activity and has been associated with an overall survival benefit.


537 ASH denotes this abstract as clinically relevant

Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, et al.

In this very difficult-to-treat patient population, an ORR of 39 percent and an RBC and platelet TI rate of 36 percent were achieved. The median OS was 12.6 months. The study authors suggest that the Ven + Aza treatment leads to significant clinical benefits. Additional analyzes will be presented in the oral session.



Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, et al.

TAG monotherapy first-line in patients with CMML shows significant clinical activity in patients with high-risk disease as well as in patients with R/R disease. The well-tolerated TAG therapy has a manageable and predictable safety profile. The study authors suggest that TAG could offer a novel targeted approach for patients with CMML.



Xinping Zhou, Fanjun Meng, Yanjuan Lin, et al.

Decitabine plus (all-trans retinoic acid) ATRA achieved an OR rate of 85.2 percent in the MDS subtype EB. The study authors conclude that this therapy may be a new treatment option for EB patients.



Meagan A. Jacoby, David A. Sallman, Bart L. Scott, et al.

CPX-351 (a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1: 5 molar drug ratio) shows a tolerable safety and a promising efficacy profile in an MDS population with a higher risk suitable for transplantation. Updated safety and efficacy results will be presented in the oral session.